<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04645446</url>
  </required_header>
  <id_info>
    <org_study_id>049/SI</org_study_id>
    <secondary_id>2019-000747-27</secondary_id>
    <nct_id>NCT04645446</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Two Different Concentrations (0.5% and 1%) of Progesterone Topical Gel Compared to Placebo in Patients Diagnosed With Moderate to Severe Dry Eye Syndrome</brief_title>
  <acronym>ProGIFT</acronym>
  <official_title>A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase II Study to Evaluate the Safety and Efficacy of Pro-ocular™ 0.5% and 1% in Patients With Dry Eye Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SIFI SpA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SIFI SpA</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group, Phase 2 clinical&#xD;
      trial.&#xD;
&#xD;
      The study objective is to evaluate the safety and efficacy of two different concentrations&#xD;
      (0.5% and 1%) of progesterone topical gel compared to placebo, when administered twice a day&#xD;
      for 3 months (12 weeks) in patients diagnosed with moderate to severe dry eye syndrome.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 18, 2021</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Allocation Ratio = 1:1:1</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Corneal Fluorescein Staining</measure>
    <time_frame>Week 12 (Day 84) (with Last Observation Carried Forward (LOCF) imputation)</time_frame>
    <description>Mean change from baseline (Visit 1 pre-dose) in corneal fluorescein staining assessed by NEI scale at Week 12 (Day 84) (with Last Observation Carried Forward (LOCF) imputation)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>SANDE questionnaire</measure>
    <time_frame>Week 12 (Day 84) (with Last Observation Carried Forward (LOCF) imputation)</time_frame>
    <description>Mean change from baseline (Visit 1 pre-dose) in sum of frequency and intensity of dryness/irritation patient feeling assessed by SANDE questionnaire at Week 12 (Day 84) (with LOCF imputation)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Corneal fluorescein staining</measure>
    <time_frame>Week 12 (Day 84)</time_frame>
    <description>Mean change from baseline (Visit 1 pre-dose) in corneal fluorescein staining assessed by NEI scale at Week 12 (Day 84).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SANDE questionnaire</measure>
    <time_frame>Week 12 (Day 84)</time_frame>
    <description>Mean change from baseline (Visit 1 pre-dose) in sum of frequency and intensity of dryness/irritation patient feeling assessed by SANDE questionnaire at Week 12 (Day 84).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conjunctival fluorescein staining</measure>
    <time_frame>Week 12 (Day 84) (with Last Observation Carried Forward (LOCF) imputation)</time_frame>
    <description>Mean change from baseline (Visit 1 pre-dose) in conjunctival fluorescein staining assessed by NEI scale at Week 12 (Day 84) (with LOCF imputation).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conjunctival fluorescein staining</measure>
    <time_frame>Week 12 (Day 84)</time_frame>
    <description>Mean change from baseline (Visit 1 pre-dose) in conjunctival fluorescein staining assessed by NEI scale at Week 12 (Day 84).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corneal fluorescein staining</measure>
    <time_frame>Week 2, 4, 8 (Day 14, 28, 56)</time_frame>
    <description>Mean change from baseline (Visit 1 pre-dose) in corneal fluorescein staining assessed by NEI scale at Week 2, 4, 8 (Day 14, 28, 56) as intermediate study visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SANDE questionnaire</measure>
    <time_frame>Week 2, 4, 8, 16 (Day 14, 28, 56,114)</time_frame>
    <description>Mean change from baseline (Visit 1 pre-dose) in sum of frequency and intensity of dryness/irritation patient feeling assessed by SANDE questionnaire at Week 2, 4, 8, 16 (Day 14, 28, 56,114) as intermediate study visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conjunctival fluorescein staining</measure>
    <time_frame>Week 2, 4, 8 (Day 14, 28, 56)</time_frame>
    <description>Mean change from baseline (Visit 1 pre-dose) in conjunctival fluorescein staining assessed by NEI scale at Week 2, 4, 8 (Day 14, 28, 56) as intermediate study visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-Invasive Keratograph Tear Film Break Up (NIKBUT) Time (NIKBUT)</measure>
    <time_frame>Week 2, 4, 8, 12 (Day 14, 28, 56, 84)</time_frame>
    <description>Mean change from baseline (Visit 1 pre-dose) in Non-Invasive Keratograph Tear Film Break Up Time (NIKBUT) at each applicable post-baseline visit [Week 2, 4, 8, 12 (Day 14, 28, 56, 84)].</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fluorescein Tear Film Break Up Time (TBUT)</measure>
    <time_frame>Week 12 (Day 84)</time_frame>
    <description>Mean change from baseline (Visit 1 pre-dose) in Fluorescein Tear Film Break Up Time (TBUT) at Week 12 (Day 84).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tear meniscus height (TMH)</measure>
    <time_frame>Week 2, 4, 8, 12 (Day 14, 28, 56, 84)]</time_frame>
    <description>Mean change from baseline (Visit 1 pre-dose) in Tear meniscus height (TMH) at each applicable post-baseline visit [Week 2, 4, 8, 12 (Day 14, 28, 56, 84)].</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Schirmer test</measure>
    <time_frame>Week 4 (Day 28) and Week 12 (Day 84)</time_frame>
    <description>Mean change from baseline (Visit 0 Screening) in Schirmer test at Week 4 (Day 28) and at Week 12 (Day 84).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dry Eye-Related Quality-of-Life (DEQS) questionnaire</measure>
    <time_frame>Each applicable post baseline visit</time_frame>
    <description>Impact of dry eye on quality of life by using Dry Eye-Related Quality-of-Life (DEQS) questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analogue Scale</measure>
    <time_frame>Each applicable post baseline visit</time_frame>
    <description>Absolute score of each symptom item in Visual Analogue Scale to each post baseline visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analogue Scale</measure>
    <time_frame>Week 2, 4, 8, 12 (Day 14, 28, 56, 84)</time_frame>
    <description>Mean change from baseline (Visit 1 pre-dose) in Visual Analogue Scale 7 symptoms items to each applicable post-baseline visit [Week 2, 4, 8, 12 (Day 14, 28, 56, 84)].</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corneal Sensitivity</measure>
    <time_frame>Week 4, 12 (Day 28, 84)</time_frame>
    <description>Mean change from baseline (Visit 1 pre-dose) in Corneal Sensitivity to each applicable postbaseline visit [Week 4, 12 (Day 28, 84)].</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Slit Lamp Examination</measure>
    <time_frame>Week 2, 4, 8, 12 (Day 14, 28, 56, 84)</time_frame>
    <description>Mean change from baseline (Visit 0 Screening) in Slit Lamp Examination to each applicable post-baseline visit [Week 2, 4, 8, 12 (Day 14, 28, 56, 84)].</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">105</enrollment>
  <condition>Dry Eye Disease</condition>
  <arm_group>
    <arm_group_label>Pro-ocular™ 1% Progesterone EP topical gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multidose formulation despensing unit doses of 0.07 g of topical gel containing 0.7 mg of progesterone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pro-ocular™ 0.5% Progesterone EP topical gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multidose formulation despensing unit doses of 0.07 g of topical gel containing 0.35 mg of progesterone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo topical gel</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Multidose formulation identical in appearance to Experimental Products despensing unit doses of 0.07 g of topical gel containing 0 mg of progesterone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pro-ocular gel</intervention_name>
    <description>Topical gel in multidose formulation to be applied laterally to the forehead twice a day, morning and night for 3 months</description>
    <arm_group_label>Pro-ocular™ 0.5% Progesterone EP topical gel</arm_group_label>
    <arm_group_label>Pro-ocular™ 1% Progesterone EP topical gel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo gel</intervention_name>
    <description>Topical gel in multidose formulation to be applied laterally to the forehead twice a day, morning and night for 3 months</description>
    <arm_group_label>Placebo topical gel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients (male or female) ≥ 18 years of age.&#xD;
&#xD;
          2. Able and willing to provide voluntary written Informed Consent prior to any study&#xD;
             related procedure.&#xD;
&#xD;
          3. Patients must be diagnosed with any type of dry eye at least 3 months before screening&#xD;
             (Visit 0).&#xD;
&#xD;
          4. Have all the following in the same eye at Visit 0:&#xD;
&#xD;
               -  Fluorescein staining (Cornea) on NEI (National Eye Institute) grading scale &gt; 3&#xD;
&#xD;
               -  Average Tear Film Break up Time ≤ 5 seconds&#xD;
&#xD;
               -  Schirmer Test (without anesthesia) ≥ 1 and &lt; 10mm&#xD;
&#xD;
          5. Be able and willing to follow instructions, including participation in all study&#xD;
             assessments and visits, according to the opinion of the investigator.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Comorbidity with other severe or chronic conditions that in the judgment of the&#xD;
             investigator will interfere with study assessment, such as such as glaucoma, active&#xD;
             neuronal trigeminal disease, neuralgia.&#xD;
&#xD;
          2. Best corrected visual acuity (BCVA) baseline &lt;20/200.&#xD;
&#xD;
          3. Condition or history other than ocular that, in the opinion of the investigator, may&#xD;
             interfere significantly with the patient's participation in the study, such as&#xD;
             dementia, psychosis, Parkinson's disease (interference).&#xD;
&#xD;
          4. Patient using a contact ocular lens within 7 days prior to administration of the first&#xD;
             dose and not willing to cease using them during all study duration.&#xD;
&#xD;
          5. Female patients who are pregnant, nursing an infant, or planning a pregnancy or&#xD;
             lactating at Screening Visit.&#xD;
&#xD;
          6. Females who are of childbearing potential and not taking adequate contraceptive&#xD;
             precautions are excluded from the trial. Females of childbearing potential taking&#xD;
             acceptable non-hormonal contraceptive precautions can be included (See Note A).&#xD;
&#xD;
          7. Males with partners who are pregnant or lactating or of childbearing potential and are&#xD;
             unwilling to use condoms for the duration of the study.&#xD;
&#xD;
          8. A known adverse reaction and/or sensitivity to the study drug or its components.&#xD;
&#xD;
          9. Use of topical ocular cyclosporine, corticosteroids or any other topical&#xD;
             anti-inflammatory treatments within 15 days prior to Visit 0 and during all study&#xD;
             duration.&#xD;
&#xD;
         10. Routine use (more than twice a week) of a chlorinated swimming pool during the study&#xD;
             period&#xD;
&#xD;
         11. Unwilling or unable to cease using during the study period the forbidden medications:&#xD;
&#xD;
               -  Any topical ocular ointments or gels&#xD;
&#xD;
               -  Topical and systemic glaucoma therapies&#xD;
&#xD;
               -  Systemic drugs with anticholinergic activity: anticonvulsants, antihistamines,&#xD;
                  antipsychotics, antidepressants, antimuscarinics, anti-Parkinson agents,&#xD;
                  cardiovascular agents (disopyramide), gastrointestinal agents, muscle relaxants,&#xD;
                  respiratory medications (pseudoephedrine, theophylline)&#xD;
&#xD;
               -  Lipidic artificial tears and artificial tears with preservative.&#xD;
&#xD;
         12. Unwilling to cease the use of sunscreen on the forehead or eye area during the study&#xD;
             period.&#xD;
&#xD;
         13. Habitual cigarette smokers (tobacco, vapor cigarettes, marijuana), smoking more than 4&#xD;
             cigarettes per day.&#xD;
&#xD;
         14. Participation in another clinical study at the same time as the present and within 30&#xD;
             days prior to Visit 0.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Gianluca Stivale</last_name>
    <phone>+39 3356070038</phone>
    <email>gianluca.stivale@sifigroup.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sebastiano Giuffrida</last_name>
    <phone>+39 3357615356</phone>
    <email>sebastiano.giuffrida@sifigroup.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ospedale San Marco - Azienda Ospedaliera Universitaria</name>
      <address>
        <city>Catania</city>
        <zip>95121,</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caterina Gagliano, MD</last_name>
      <phone>+39 3472698035</phone>
      <email>caterina_gagliano@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>A.O.U. Careggi Firenze - SOD Oculistica</name>
      <address>
        <city>Florence</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rita Mencucci, MD</last_name>
      <phone>+39 3356274390</phone>
      <email>rita.mencucci@unifi.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Policlinico G. Martino - UOC di Oftalmologia</name>
      <address>
        <city>Messina</city>
        <zip>98125</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pasquale Aragona, MD</last_name>
      <phone>+39.3483384677</phone>
      <email>paragona@unime.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Luigi Sacco Polo Universitario - Oculistica</name>
      <address>
        <city>Milan</city>
        <zip>20157</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefano Barabino, MD, PhD</last_name>
      <phone>+39 3395480804</phone>
      <email>sbarabi@tin.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>November 25, 2020</study_first_submitted>
  <study_first_submitted_qc>November 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 27, 2020</study_first_posted>
  <last_update_submitted>June 15, 2021</last_update_submitted>
  <last_update_submitted_qc>June 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Eye Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

